טוען...
Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
BACKGROUND: Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti‐VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. The safety and efficacy of these agents in preterm i...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2018
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6491066/ https://ncbi.nlm.nih.gov/pubmed/29308602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD009734.pub3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|